Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Rastogi

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Future Oncology (London, England)|February 28, 2025
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancerErika P Hamilton, Sibylle Loibl, Thomas Bachelot, et al.
Journal of the National Cancer Institute|May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancerEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
The New England Journal of Medicine|June 4, 2010
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancerSandra M Swain, Jong-Hyeon Jeong, Charles E Geyer, et al.
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2018
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast CancerAndrew D Seidman, Louise Bordeleau, Louis Fehrenbacher, et al.
JAMA Oncology|November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 TrialPatrick G Gavin, Nan Song, S Rim Kim, et al.
The Lancet. Oncology|March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialSibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 TrialEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Annals of Surgical Oncology|September 25, 2016
Poor Prognosis After Second Locoregional Recurrences in the CALOR TrialIrene L Wapnir, Shari Gelber, Stewart J Anderson, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Future Oncology (London, England)|February 28, 2025
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancerErika P Hamilton, Sibylle Loibl, Thomas Bachelot, et al.
Journal of the National Cancer Institute|May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancerEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
The New England Journal of Medicine|June 4, 2010
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancerSandra M Swain, Jong-Hyeon Jeong, Charles E Geyer, et al.
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2018
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast CancerAndrew D Seidman, Louise Bordeleau, Louis Fehrenbacher, et al.
JAMA Oncology|November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 TrialPatrick G Gavin, Nan Song, S Rim Kim, et al.
The Lancet. Oncology|March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialSibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 TrialEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Annals of Surgical Oncology|September 25, 2016
Poor Prognosis After Second Locoregional Recurrences in the CALOR TrialIrene L Wapnir, Shari Gelber, Stewart J Anderson, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Pageof 9